RxDoctor Payments DataLook up a doctor →

Nitin Chhabra, MD

Pain Medicine · Hoover, ALNPI 1811035371

Payments from drug & device makers

$9,140in general payments, 2019–2025

Across 491 payments — averaging $18.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Collegium Pharmaceutical, Inc.$697
  • Abbott$590
  • Nevro Corp.$259
  • Scilex Pharmaceuticals Inc.$247
  • plus $3K from 38 others

What the payments were for

  • Travel & lodging$90110%
  • Food & beverage$8,23390%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,140 in reported general payments places this provider in the 85th percentile of 77 pain medicine providers in Alabama.

See all pain medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$269,664
Medicare patients
332
Services billed
4,557

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl333$306,983
RelistorMethylnaltrexone Bromide56$157,041
Buprenorphine197$68,725
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen2,107$56,840
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,504$42,462
MovantikNaloxegol Oxalate45$24,800
LinzessLinaclotide38$21,872
Diclofenac Sodium198$17,614
Gabapentin1,208$13,841
Oxycodone Hcl642$10,808
NucyntaTapentadol Hcl11$9,515
Lidocaine108$9,382
Tizanidine Hcl803$8,895
Pregabalin460$7,607
Xtampza ErOxycodone Myristate16$5,505

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Nucynta, Xtampza Er$697$322,002360 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$1,666$157,04156 claims
Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate, Buprenorphine-Naloxone, Buprenorphine Hcl$46$71,081280 claims
Redhill Biopharma Inc.Movantik$165$24,80045 claims
AbbVieLinzess$208$21,87238 claims
Upsher-smith Laboratories LLCTopiramate$18$30957 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 77 pain medicine providers in Alabama.

Other pain medicine in Hoover

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →